European Parliament Clears Marketing Exclusivity For Pediatric Testing
The proposal will require new drugs to be tested specifically on children before they are cleared for pediatric use, and aims to stimulate new research into existing medicines.
Under the proposal, most pediatric drugs would receive an additional six months of patent protection. Other drugs, used for extremely rare diseases, would be patented for two extra years.
The proposal would require new drugs to be tested specifically...
To view the full article, register now.